Results 201 to 210 of about 14,495 (295)

Descriptive study of patients with uveitis attended during one-year period - diagnostic classification and treatment [PDF]

open access: yes, 2010
M V Hernández   +7 more
core   +1 more source

Guidelines for the management of non-infectious intermediate and posterior uveitis [PDF]

open access: diamond, 2018
Marta Misiuk‐Hojło   +6 more
openalex   +1 more source

Seroprevalence of equine leptospirosis in Poland (2019–2023)

open access: yesEquine Veterinary Journal, Volume 58, Issue 2, Page 523-532, March 2026.
Abstract Background Leptospirosis in horses is associated with various clinical signs, potentially leading to fatal outcomes. Additionally, the disease may pose a zoonotic risk to individuals involved in handling infected animals. Implementing a serological monitoring programme in the equine population is one of the key tools used to reduce the risk of
Jacek Żmudzki   +8 more
wiley   +1 more source

Smoking As a Risk Factor for Cystoid Macular Edema Complicating Intermediate Uveitis

open access: green, 2008
Jennifer E. Thorne   +5 more
openalex   +2 more sources

SAT0598 Systematic literature review on the efficacy and safety of immunomodulatory drugs in patients with nonifectious intermediate and posterior uveitis, panuveitis and macular oedema [PDF]

open access: bronze, 2018
A. Gómez Gómez   +7 more
openalex   +1 more source

Sex Matters: Hormonal and Chromosomal Determinants of Autoimmunity and Anti‐Cancer Immunity Across the Lifespan

open access: yesImmunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Sex plays a key role in shaping both anti‐cancer immunity and autoimmunity. Biological factors underlying sexual dimorphism have now been identified in multiple aspects of anti‐cancer immunity and autoimmunity. These factors include sex differences in hormone levels, chromosome complement, and expression of the long non‐coding RNA XIST.
Christian G. Bustillos   +4 more
wiley   +1 more source

Phase 1 Dose Escalation of Single‐Agent Mechlorethamine in Dogs With Lymphoma

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 1, Page 51-57, March 2026.
ABSTRACT Mechlorethamine is commonly prescribed to dogs at 3 mg/m2. The minimal toxicity observed indicates that higher doses of mechlorethamine are likely tolerable. The primary objective of this study was to determine the maximally tolerated dose (MTD) of mechlorethamine in dogs with lymphoma.
Laura E. Chadsey   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy